Expert.ai Named to the RegTech100 for 2026
Get Alerts IM Hot Sheet
Join SI Premium – FREE
EIX-Regulation solution strengthens the company's leadership in helping banks and financial institutions stay ahead of regulatory change.
Regulatory activity across
Part of the Expert.ai EidenAI Suite, EIX-Regulation applies advanced AI to help banking and financial services organizations continuously monitor evolving legislation and regulatory updates. By automating the monitoring, analysis and extraction of relevant information, the solution reduces sanction-related risks and alleviates the heavy operational burden of manual regulatory tracking and change-management activities. It also helps teams keep pace with fast-moving regulatory developments, accelerate identification of required compliance actions and mitigate potential reputational risk.
"We're proud to once again be recognized among the 100 most innovative RegTech companies," said
Expert.ai has further enhanced EIX-Regulation to better support the priorities of banks, insurers and financial institutions. The product roadmap includes new capabilities designed to strengthen and simplify the work of compliance teams, supporting their work rather than replacing it. In a highly regulated environment, effective AI must remain explainable, traceable and controllable. This is where Expert.ai's hybrid technology model best delivers its full value and potential.
About Expert.ai
Expert.ai is a company specializing in the implementation of enterprise artificial intelligence solutions to create business value, listed on the Euronext Growth Milan market (EXAI: IM) and operating in
For more information, visit https://www.expert.ai
View original content to download multimedia:https://www.prnewswire.com/news-releases/expertai-named-to-the-regtech100-for-2026-302637706.html
SOURCE expert.ai
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Miranda Lambert To Kick Off Salvation Army's Red Kettle Campaign With Dallas Cowboys Thanksgiving Game Halftime Performance
- Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 202
- Ethereum Price Prediction: ETH Near $2,324 as Remittix’s $0.28 Entry Meets Its $0.46 Final Presale Stage
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share